Literature DB >> 10728257

The maternal and child health sites' practices regarding HIV education, counseling, and testing of women of reproductive age in Chicago: barriers to universal implementation.

A Rahimian1, M Driscoll, D Taylor.   

Abstract

OBJECTIVES: Women of reproductive age are increasingly at risk for human immunodeficiency virus (HIV) infection. Recent advances in reducing perinatal transmission have resulted in official guidelines on universal HIV education, counseling, and voluntary testing of women of reproductive age, especially pregnant women. This study assesses to what extent the maternal child health (MCH) sites are implementing these guidelines with their female patient population (including pregnant women) and examines the barriers that prevent them from implementing these guidelines.
METHOD: The study uses survey data from 92 hospitals and community health centers offering MCH services in Chicago regarding their providers' practices on HIV education, counseling, and testing, implementation of zidovudine (ZDV) therapy to reduce perinatal transmission, and the barriers to implementing these services. In addition, 20 taped in-depth interviews were conducted with experts to examine the barriers to universal implementation.
RESULTS: Almost half (45% of perinatal care and 50% of family planning providers) of the institutions are not consistently offering HIV testing. One-third of those institutions that offer testing are not offering pretest counseling. Thirty-nine percent of the perinatal care providers in these institutions are not providing posttest counseling to HIV-negative women. Over one-third (35%) of these institutions reported that they are not set up to implement ZDV therapy during labor and delivery. Almost half (49%) had no protocols for ZDV therapy in place. Barriers to implementation included lack of provider training, limited staff time, physician resistance, unavailability or avoidance to seek perinatal care by high-risk women, cost, absence of a statewide and hospital-specific plan, lack of reproductive choice focus in posttest counseling, lack of provider knowledge about the administration of ZDV or its availability during labor, and lack of consumer education on perinatal risk reduction.
CONCLUSIONS: MCH sites and their providers need assistance to overcome many barriers they face to implement universal HIV education, counseling, and testing of women of reproductive age.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10728257     DOI: 10.1023/a:1021893525536

Source DB:  PubMed          Journal:  Matern Child Health J        ISSN: 1092-7875


  21 in total

1.  Pregnant women eligible for single-dose nevirapine study.

Authors:  J S James
Journal:  AIDS Treat News       Date:  1997-10-03

2.  AIDS in women in the United States. Recent trends.

Authors:  P M Wortley; P L Fleming
Journal:  JAMA       Date:  1997-09-17       Impact factor: 56.272

3.  Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. Perinatal AIDS Collaborative Transmission Studies.

Authors:  D T Dunn; M L Newell; M J Mayaux; C Kind; C Hutto; J J Goedert; W Andiman
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-10

4.  Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention.

Authors:  R D Gorsky; P G Farnham; W L Straus; B Caldwell; D R Holtgrave; R J Simonds; M F Rogers; M E Guinan
Journal:  Public Health Rep       Date:  1996 Jul-Aug       Impact factor: 2.792

5.  Identification of psychobiological stressors among HIV-positive women. HIV Neurobehavioral Research Center (HNRC) Group.

Authors:  S J Semple; T L Patterson; L R Temoshok; J A McCutchan; K A Straits-Tröster; J L Chandler; I Grant
Journal:  Women Health       Date:  1993

6.  Social interventions in the care of human immunodeficiency virus (HIV)-infected pregnant women.

Authors:  C Levine; M H Allen
Journal:  Semin Perinatol       Date:  1995-08       Impact factor: 3.300

7.  Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.

Authors:  P J Boyer; M Dillon; M Navaie; A Deveikis; M Keller; S O'Rourke; Y J Bryson
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

8.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.

Authors:  G Scarlatti; J Albert; P Rossi; V Hodara; P Biraghi; L Muggiasca; E M Fenyö
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

9.  Trends in zidovudine prescription for pregnant women infected with HIV.

Authors:  A Lansky; J L Jones; P C Wan; M L Lindegren; P Wortley
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-07-01

10.  U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1995-07-07
View more
  1 in total

1.  Implementation of guidelines for HIV counseling and voluntary HIV testing of pregnant women.

Authors:  E Joo; A Carmack; E Garcia-Buñuel; C J Kelly
Journal:  Am J Public Health       Date:  2000-02       Impact factor: 9.308

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.